Posted by Michael Wonder on 02 Oct 2018
Denmark funds Vertex’s cystic fibrosis drug Orkambi, UK talks deadlocked
2 October 2018 - As uncertainty hangs over the availability of Vertex’s cystic fibrosis drug in England, the company has signed an agreement that gives Danish patients access to Orkambi.
The access contract, agreed by Vertex and the Danish pharmaceutical and procurement organisation, Amgros, covers current and future medicine for cystic fibrosis (CF).
The news was welcomed, as Orkambi is the first medicine to treat the underlying cause of CF in people aged six and over who have two copies of the F508del mutation.
